Clareo Health | SAPHIR : Assessment of Predictive Factors for Persistence of Treatment After Initiation of Adalimumab With a Biosimilar (Adalimumab Fresenius KaBI or Substitution of Reference Adalimumab With the Fresenius Kabi Adalimumab Biosimilar in Patients With Chronic Inflammatory Diseases
SAPHIR : Assessment of Predictive Factors for Persistence of Treatment After Initiation of Adalimumab With a Biosimilar (Adalimumab Fresenius KaBI or Substitution of Reference Adalimumab With the Fresenius Kabi Adalimumab Biosimilar in Patients With Chronic Inflammatory Diseases
In a population of adult patients who are targeted to initiate adalimumab or previously treated with Humira® to get switched to a biosimilar (FK adalimumab) and followed up for a period of 12 months under routine medical practice conditions.
* Primary objective: to define predictive factors for the persistence of treatment
* Secondary objectives:
* To assess the therapeutic benefit and the tolerability of the treatment
* To describe the reasons for treatment discontinuations occurring during follow-up
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient aged 18 years or over
Patient who have been informed of the objectives and the conditions of the study and who did not object to its participation
Patient diagnosed with one chronic inflammatory rheumatological (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis) or chronic inflammatory bowel (Crohn's disease, ulcerative colitis) diseases
Patient for whom the investigator has decided, with patient's agreement and prior to inclusion:
Or to initiate adalimumab by prescribing a biosimilar (Adalimumab FK)
Either to replace Humira® with a biosimilar (AdalimumabFK)
You may not be if
Patient enrolled in an interventional therapeutic trial at the time of inclusion
Patient refusing or unable to comply with the study follow-up procedures (patient not contactable by telephone, unable to complete the self-administered questionnaire, or having poor French language skills, etc.)
